Sharif Ahmed, M.S, RAC, new Principal Consultant at Lachman Consultant Services, Inc.

We are pleased to announce that Sharif Ahmed has accepted the position of Principal Consultant in the Regulatory Practice at Lachman Consultants, effective February 20, 2017.

Mr. Ahmed has been functioning as a Senior Associate in the Regulatory Practice at Lachman Consultants since January 2016. He is a seasoned Regulatory professional with nearly 30 years of progressive responsibilities and is highly knowledgeable of the product approval processes of both the U.S. FDA and Health Canada. He is a skilled leader of strategy development, regulatory submissions, and inspections and provides services in Regulatory Affairs, Quality, Clinical and Non-clinical development.

Prior to joining Lachman, Mr. Ahmed served as Director, Regulatory Affairs at Par Sterile Products, was Director of Regulatory Affairs at Teva Pharmaceuticals; served as Associate Director, Manager of Regulatory Affairs, and Senior Technical Group Leader at Barr Laboratories, Inc. and as Senior Regulatory Affairs Associate at Faulding Pharmaceutical Co. He shares his expertise with students at Long Island University serving as Adjunct Professor of Drug Regulatory Affairs courses.

Mr. Ahmed was awarded an M.S. in Pharmaceutical Marketing and Health Care Administration from Long Island University of New York.

We welcome Sharif to his new role of Principal Consultant and wish him a long and successful career with Lachman Consultants.

For more than 30 years, Lachman Consultants has been the leader in providing cost-effective consultation and remediation services to the worldwide pharmaceutical, biotechnology, biologic, medical device, diagnostic and dietary supplement industries. With its strong and extensive cadre of consultant specialists and an unparalleled management team, its Compliance, Science & Technology, and Regulatory Practices provide the most expert counsel and array of services available. Lachman Consultants is proud of its tradition of supporting industry efforts to develop and ensure safe, effective and high-quality medical products. It remains committed to helping the industry anticipate and address its challenges through the development and implementation of practical, sustainable and cost-effective solutions based on the integration of scientific principles, evolving regulatory expectations, and technology.